About this Journal Submit a Manuscript Table of Contents
Sarcoma
Volume 2013 (2013), Article ID 168145, 8 pages
http://dx.doi.org/10.1155/2013/168145
Clinical Study

A Pilot Study of Anti-CTLA4 Antibody Ipilimumab in Patients with Synovial Sarcoma

1Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY 10065, USA
2Departments of Medicine, Pediatrics, and Orthopaedics, Mount Sinai School of Medicine, 1 Gustave L. Levy Place, P.O. Box 1208, New York, NY 10029-6574, USA
3Ludwig Institute of Cancer Research, New York, NY 10065, USA
4Sarcoma and Bone Cancer Treatment Center, Dana-Farber Cancer Institute, Boston, MA 02215, USA
5University of Michigan Cancer Center, Ann Arbor, MI 48109, USA
6Medarex, Inc., Bloomsbury, NJ 08804, USA
7Bristol Myers Squibb Company, Wallingford, CT 06492, USA
8Regeneron, Inc., Tarrytown, NY 10591, USA

Received 12 December 2012; Accepted 27 January 2013

Academic Editor: Akira Kawai

Copyright © 2013 Robert G. Maki et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

How to Cite this Article

Robert G. Maki, Achim A. Jungbluth, Sacha Gnjatic, et al., “A Pilot Study of Anti-CTLA4 Antibody Ipilimumab in Patients with Synovial Sarcoma,” Sarcoma, vol. 2013, Article ID 168145, 8 pages, 2013. doi:10.1155/2013/168145